Insulin action in vascular endothelium: Potential mechanisms linking insulin resistance with hypertension

Diabetes, Obesity and Metabolism

Volumn 2, Issue 5, 2000, Pages 285-292

  Montagnani, Monica ^a   Quon, Michael J ^a  

^a NATIONAL HEART LUNG AND BLOOD INSTITUTE   (United States)

Author keywords

Endothelium; Metabolism; Nitric oxide

Indexed keywords

INSULIN; INSULIN RECEPTOR KINASE; NITRIC OXIDE; PHOSPHATIDYLINOSITOL KINASE;

BLOOD FLOW; CONTROLLED STUDY; GLUCOSE METABOLISM; HEMODYNAMICS; HOMEOSTASIS; HUMAN; HUMAN CELL; HYPERTENSION; INSULIN RESISTANCE; PATHOPHYSIOLOGY; REVIEW; SIGNAL TRANSDUCTION; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE; VASODILATATION;

EID: 0034527580     PISSN: 14628902     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1463-1326.2000.00092.x     Document Type: Review

References (75)

1. Hyperinsulinemia: A link between hypertension obesity and glucose intolerance
2. Banting lecture 1988. Role of insulin resistance in human disease
3. Role of insulin resistance in human disease (syndrome X): An expanded definition
4. Insulin resistance in essential hypertension
5. Insulin resistance is a characteristic feature of primary hypertension independent of obesity
6. Prevalence of hyperinsulinaemia in patients with high blood pressure
7. Hyperinsulinemia is associated with the incidence of hypertension and dyslipidemia in middle-aged men
8. Hypertension and associated metabolic abnormalities: The role of insulin resistance and the sympathoadrenal system
9. Insulin resistance, hyperinsulinemia, and dyslipidemia in nonobese individuals with a family history of hypertension
10. Insulin resistance, hyperinsulinemia, and coronary artery disease: A complex metabolic web
11. Chronic insulin administration elevates blood pressure in rats
12. Vascular smooth muscle cell growth and insulin regulation of mitogen-activated protein kinase in hypertension
13. Hemodynamic actions of insulin
14. Vascular reactivity
15. Hyperinsulinaemia is not linked with blood pressure elevation in patients with insulinoma
16. Regulation of muscle blood flow
17. Autoregulation of blood flow
18. Glucose delivery: A modulator of glucose uptake in contracting skeletal muscle
19. Important role of insulin and flow in stimulating glucose uptake in contracting skeletal muscle
20. Skeletal muscle blood flow independently modulates insulin-mediated glucose uptake
21. Insulin-mediated skeletal muscle vasodilation contributes to both insulin sensitivity and responsiveness in lean humans
22. Insulin resistance and vasodilation in essential hypertension: Studies with adenosine
23. Vasodilation with sodium nitroprusside does not improve insulin action in essential hypertension
24. Insulin resistance of glucose uptake in skeletal muscle cannot be ameliorated by enhancing endothelium-dependent blood flow in obesity
25. Role of blood flow in regulating insulin-stimulated glucose uptake in humans: Studies using bradykinin, [15O]water, and [18F]fluoro-deoxy- glucose and positron emission tomography
26. 2O, [18F]fluoro-2-deoxy-D-glucose, and positron emission tomography
27. Sodium nitroprusside increases human skeletal muscle blood flow, but does not change flow distribution or glucose uptake
28. The coupling of glucose metabolism and perfusion in human skeletal muscle. The potential role of endothelium-derived nitric oxide
29. Role of blood flow in the regulation of muscle glucose uptake
30. Insulin-mediated skeletal muscle vasodilation is nitric oxide dependent: A novel action of insulin to increase nitric oxide release
31. Nitric oxide release accounts for insulin's vascular effects in humans
32. Effect of perfusion rate on the time course of insulin-mediated skeletal muscle glucose uptake
33. Impaired insulin-mediated skeletal muscle blood flow in patients with NIDDM
34. Decreased effect of insulin to stimulate skeletal muscle blood flow in obese man. A novel mechanism for insulin resistance
35. Improvement in glucose tolerance and insulin resistance in obese subjects treated with troglitazone
36. Enhancement of insulin sensitivity by troglitazone lowers blood pressure in diabetic hypertensives
37. Metformin improves glucose, lipid metabolism, and reduces blood pressure in hypertensive, obese women
38. Blood pressure lowering by pioglitazone: Evidence for a direct vascular effect
39. A comparison of the effects of hydrochlorothiazide and captopril on glucose and lipid metabolism in patients with hypertension
40. ACE-inhibition increases hepatic and extrahepatic sensitivity to insulin in patients with type 2 (non-insulin-dependent) diabetes mellitus and arterial hypertension
41. ACE inhibition improves insulin-sensitivity in aged insulin-resistant hypertensive patients
42. Effects of an angiotensin-converting enzyme inhibitor, Ramipril, on cardiovascular events in high-risk patients
43. Imidapril, an angiotensin-converting enzyme inhibitor, improves insulin sensitivity by enhancing signal transduction via insulin receptor substrate proteins and improving vascular resistance in the Zucker fatty rat
44. Effect of captopril, losartan, and bradykinin on early steps of insulin action
45. Crosstalk between insulin and angiotensin II signalling systems
46. Angiotensin II inhibits insulin signalling in aortic smooth muscle cells at multiple levels: A potential role for serine phosphorylation in insulin/angiotensin II crosstalk
47. Hypertension, hypertriglyceridemia, and impaired endothelium-dependent vascular relaxation in mice lacking insulin receptor substrate-1
48. Insulin action and endothelial function
49. Effects of free fatty acids on glucose transport and IRS-1-associated phosphatidylinositol 3-kinase activity
50. Overnight lowering of free fatty acids with Acipimox improves insulin resistance and glucose tolerance in obese diabetic and nondiabetic subjects
51. Oleic acid inhibits endothelial nitric oxide synthase by a protein kinase C-independent mechanism
52. Elevated circulating free fatty acid levels impair endothelium-dependent vasodilation
53. Cholesterol lowering and endothelial function
54. Structure-function aspects in the nitric oxide synthases
55. Hypertension in mice lacking the gene for endothelial nitric oxide synthase
56. Insulin signalling: Metabolic pathways and mechanisms for specificity
57. Insulin-stimulated production of nitric oxide is inhibited by wortmannin: Direct measurement in vascular endothelial cells
58. Roles for insulin receptor, PI 3-kinase, and Akt in insulin signalling pathways related to production of nitric oxide in human vascular endothelial cells
59. Insulin receptors in human endothelial cells: Identification and characterization
60. Roles of 1-phosphatidylinositol 3-kinase and ras in regulating translocation of GLUT4 in transfected rat adipose cells
61. Physiological role of Akt in insulin-stimulated translocation of GLUT4 in transfected rat adipose cells
62. Expression of a constitutively active Akt Ser/Thr kinase in 3T3-L1 adipocytes stimulates glucose uptake and glucose transporter 4 translocation
63. Inhibition of glycogen synthase kinase-3 by insulin mediated by protein kinase B
64. Activation of nitric oxide synthase in endothelial cells by Akt-dependent phosphorylation
65. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt
66. Effects of overexpressing wild-type and mutant PDGF receptors on translocation of GLUT4 in transfected rat adipose cells
67. The inability of phosphatidylinositol 3-kinase activation to stimulate GLUT4 translocation indicates additional signalling pathways are required for insulin-stimulated glucose uptake
68. Activation of phosphoinositide 3-kinase is required for PDGF-stimulated membrane ruffling
69. Characterization of selective resistance to insulin signalling in the vasculature of obese Zucker (fa/fa) rats
70. Vasodilator response to systemic but not to local hyperinsulinemia in the human forearm
71. The sympathetic nervous system in hypertension and renal disease
72. Effects of sympathectomy and nitric oxide synthase inhibition on vascular actions of insulin in humans
73. Insulin stimulates endothelin-1 secretion from human endothelial cells and modulates its circulating levels in vivo
74. Insulin stimulates both endothelin and nitric oxide activity in the human forearm
75. Insulin potentiates platelet-derived growth factor action in vascular smooth muscle cells